NEW YORK, May 23, 2005 (PRIMEZONE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company, including recent clinical results and upcoming milestones at the Needham & Company Fourth Annual Biotechnology Conference in New York City. Mr. Weiss' presentation will take place on Wednesday, May 25, 2005 at 4:00 p.m. Eastern Time in the L'Orangerie Room of the New York Palace Hotel. A live audio webcast of Mr. Weiss' presentation will be available at http://www.wsw.com/webcast/needham11/kerx/. An archived version of the webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is in a Phase 2 clinical program and for which a pivotal Phase 3 and Phase 4 program is pending commencement under an SPA with the FDA. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt and other important signal transduction pathways, which is in Phase 2 clinical development. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.